To investigate the inflammatory metabolic pathways involved in the secondary loss of response to infliximab in patients with Crohn's disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300072990

Enrollment

Unknown

Registered

2023-06-29

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's disease

Interventions

Case series:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) 18-70 years old; 2) BMI between 18.9 and 23.9; 3) CD patients with stable follow-up.

Exclusion criteria

Exclusion criteria: 1) serious underlying metabolic diseases (hypertension, hyperlipidemia, diabetes, cancer, etc.) that failed to be relieved by standardized clinical medication; 2) Discontinuation due to allergy or other adverse reactions; 3) Use of other biological agents before IFX infusion.

Design outcomes

Primary

Measure	Time frame
loss response to infliximab;	—

Countries

China

Contacts

Public ContactJun Shen

Baoshan Branch of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine

shenjun@renji.com+86 136 5182 9887

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026